DRUG
Oxytocin
10 iu will be given intravenously.
Status
Unknown
Phase
Not applicable
Enrollment
80
Locations
0
Results
Not posted
Publications
12
Study summary
Comparison between Carbetocin and Oxytocin as prophylaxis against Primary Postpartum Hemorrhage.
Patients will be allocated randomly by simple randomization into either 1- the control group which will be given 10 IU oxytocin intravenously, OR 2- the treatment group which will be given 100 micrograms of carbetocin intravenously. The trial will be conducted on patients with high risk of developing atonic primary postpartum hemorrhage. The trial will be single blinded. All patients fulfilling the inclusion criteria undergoing elective Caesarean section will be approached by the treating physician and will be asked to participate in the study. An informed written consent will be taken from each patient. The data collected will include base line characteristics such as age, parity, body mass index, the risk for Postpartum hemorrhage in each patient, amount of blood loss, blood units given, complete blood picture (pre and post operative) and coagulation profile.
Interventions
DRUG
10 iu will be given intravenously.
DRUG
100 micrograms will be given intravenously.
Timeline
First posted
Jul 29, 2022
Study start
Jul 28, 2022
Primary completion
Dec 30, 2022
Study completion
Dec 30, 2022
Results posted
Not reported
Registry updated
Aug 2, 2022
Outcomes
Amount of Postpartum Hemorrhage
Time frame · First 24 hours after Delivery
Amount of Blood Loss in milliliters. Pre-operative patient's Hemoglobin (Hb) level and 24 hours post-operative will be assessed to quantify amount of blood loss. Additionally, all towels prepared for CS will weighed, and the weight will be marked on each pack before autoclaving. All towels (used and unused) will be weighed again after use, and a difference of 1 gm will be considered as equivalent to 1 mL of absorbed blood.
Not reported in the indexed record.
Eligibility
Inclusion Criteria: * • High risk patients for post-partum hemorrhage who will subjected to Caeserean section either elective or in labour at or after 36 weeks of gestation. This should include one or more of the following: 1. History of postpartum hemorrhage. 2. Delivery of a macrosomic baby (\> 4000 g). 3. Multiple gestation. 4. Polyhydramnios. 5. Grand Multiparity. 6. Interstitial or submucous fibroid. (Single larger than 4 cm or Multiple myomata) 7. Chorioamnionitis. Exclusion Criteria: * • Patients without high risk for post-partum hemorrhage. * Patients at high risk for postpartum hemorrhage but will deliver vaginally. * Patients with medical disorders complicating pregnancy. * Patients with coagulation defects. * Preterm pregnancies.
Study locations
No country data reported. Showing up to 24 locations stored in the fast local snapshot.
No study locations reported.
Publications
Related trials
Alex Ekwueme Federal University Teaching Hospital · Blood Loss, Surgical
Early Phase 1
Not yet recruiting
900
2026-07
Mansoura University · Postpartum Hemorrhage · Uterine Atony
Phase 4
Not yet recruiting
332
2026-06
Sheba Medical Center · Postpartum Hemorrhage · Twin Pregnancy
Phase 4
Recruiting
120
2026-05
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Postpartum Hemorrhage
Not applicable
Recruiting
32
2026-04
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Post Partum Hemorrhage
Not applicable
Recruiting
160
2026-04
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Postpartum Hemorrhage (Primary)
Not applicable
Recruiting
120
2026-04
Ankara Etlik City Hospital · Postpartum Hemorrhage \(PPH\)
Not applicable
Completed
300
2026-02
Oslo University Hospital · Pregnancy Complications
Phase 4
Completed
240
2026-02
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.